PharmaFocus Today – Page 93 – media

Midea Group established the Medical Division and released Midea Medical’s annual new products

On April 8, the 91st China International Medical Equipment Fair (CMEF) opened. During the exhibition, Midea Medical held the “AI All-dimensional Intelligent Transformation 2025 Midea Medical Annual New Product Release and China Backbone Guardian Plan Launch Meeting” and officially announced the establishment of Midea Medical Division. As one of the six major business sectors of Midea Group, Midea Medical is a major breakthrough in Midea Group’s diversified development strategy. Midea Medical has the accumulation of Wandong Medical in medical diagnostic equipment and intelligent imaging solutions, Kuka Medical’s cutting-edge technology in the field of surgical robots and rehabilitation robots, Midea Biomedical’s professional advantages in medical cold chain refrigeration, Swisslog Medical’s mature solutions in hospital logistics and pharmacy automation, and Midea Building Technology’s strength in the construction and operation of smart hospitals. The synergy of these advantageous resources will further enhance Midea Medical’s industrial competitiveness. Midea Medical will also rely on Midea ...
- Source: drugdu
- 520
- April 14, 2025
Operating income of 3.07 billion yuan in 2024, a year-on-year increase of 13.32%

The 2024 annual report recently released by Ruipu Bio shows that the company adheres to technological innovation and strategic layout, and achieves operating income of 3.07 billion yuan, a year-on-year increase of 13.32%; net profit attributable to shareholders of listed companies is 301 million yuan; it plans to pay 3 yuan (including tax) for every 10 shares. In 2024, the company invested 238 million yuan in research and development, accounting for 7.76% of operating income, and added 10 new veterinary drug registration certificates and 29 authorized patents. In the field of biological products, cutting-edge technologies such as mRNA technology platform and recombinant duck plague virus vector vaccine have made breakthroughs. Among them, the independently developed cat triple vaccine “Ruimiaoshu” has become the first local listed product. The enrofloxacin hydrochloride pellet coating preparation developed by the Drug Research Institute reduces the cost of medication by 25%-50%, which is highly recognized by ...
- Source: drugdu
- 167
- April 14, 2025
CanSino Biologics and Jiankai Technology have a strategic partnership to explore new mRNA vaccine tumor immunity solutions

On April 9, according to the official microblog of CanSino Biologics, CanSino Biologics (Shanghai) Co., Ltd., a subsidiary of CanSino Biologics, and Tianjin Jiankai Technology Co., Ltd. (hereinafter referred to as “Jiankai Technology”), a wholly-owned subsidiary of Jiankai Technology, recently signed a cooperative development agreement. The two parties will jointly promote the clinical research project of mRNA vaccines for the treatment of glioblastoma (GBM), and it is expected that the first patient will be dosed this year. https://finance.eastmoney.com/a/202504093371737123.html
- Source: drugdu
- 179
- April 14, 2025
Products will not be easily replaced, and the impact of tariffs is limited.

On April 8, local time, US President Trump delivered a speech saying that the United States will impose tariffs on drugs. This news has once again attracted market attention to pharmaceutical companies that were “exempted” in the previous round of tariff increases. From the market reaction on the 9th, the decline of individual stocks in the API sector was the largest. Data shows that 90% of active pharmaceutical ingredients (API) in the US market rely on imports, of which 60% come from China. In the short term, API companies that rely on US export business may be affected by the tax increase, but in the long term, the tax increase on imported APIs may cause a surge in the cost of US pharmaceutical research and development and manufacturing. Industry insiders believe that US tariffs mainly have a certain impact on the low-end pharmaceutical industry, and have little impact on the ...
- Source: drugdu
- 434
- April 14, 2025
The United States may impose tariffs on drug imports. Many pharmaceutical companies responded with “close attention”

According to CCTV News, on April 8, there was news that the United States would impose tariffs on drugs. It is understood that the broad tariffs on US imports announced last week did not involve drugs, but at that time, it was reported that drugs would face separate tariffs. Pharmaceutical companies such as Hanyu Pharmaceutical, Kelun Pharmaceutical, and Tonghua Dongbao responded. Hanyu Pharmaceutical responded on April 9: “The company’s current products sold to the United States are mainly liraglutide and some raw materials. We and our partners are closely following the relevant developments. The relevant response needs to be studied after the specific situation of the US drug tariffs is clarified. The company has also been planning to expand into the European or Southeast Asian markets to reduce its dependence on the US market.” Kelun Pharmaceutical’s Securities Department responded: “We have just seen this news. The company’s relevant departments are ...
- Source: drugdu
- 297
- April 11, 2025
The United States will impose tariffs on drugs

On April 8, local time, US President Trump gave a speech saying that the United States will impose tariffs on drugs. Trump said that the United States does not produce its own drugs and other products that improve health. The price the United States pays for drugs is often many times higher than that of countries that produce drugs. Trump believes that once tariffs are imposed on drugs, pharmaceutical companies will open factories in the United States because the United States is the “largest market.” Last week, Trump announced a wide range of tariffs on US imports that did not involve drugs, but he said that drugs would face separate taxes. European pharmaceutical companies have warned in a meeting with the President of the European Commission on the 8th that US tariffs will accelerate the trend of the industry shifting from Europe to the United States. The pharmaceutical industry trade ...
- Source: drugdu
- 170
- April 11, 2025
Zhifei Biotech’s bivalent dysentery vaccine is ready to start enrolling subjects

On April 8, Zhifei Biotech (300122) issued an announcement that it was recently learned that the bivalent dysentery conjugate vaccine developed by the company’s wholly-owned subsidiary Zhifei Green Bamboo has obtained the Phase III clinical trial approval from the Bangladesh Drug Administration and is ready to start enrolling subjects. The vaccine is designed to prevent bacterial dysentery caused by Shigella flexneri and Shigella sonnei, which affects 164.7 million people worldwide each year, especially in developing countries and children under 5 years old. In the first three quarters of 2024, Zhifei Biotech achieved revenue of 22.786 billion yuan and net profit attributable to the parent of 2.151 billion yuan. https://finance.eastmoney.com/a/202504083369655980.html
- Source: drugdu
- 193
- April 11, 2025
The oral vaccine developed by Kangtai Biological and its subsidiaries has started Phase III clinical trials

On April 9, Kangtai Biological (300601) issued an announcement, announcing that the oral pentavalent reassortant rotavirus attenuated live vaccine (Vero cells) developed by it and its wholly-owned subsidiary Minhai Biological has completed the preparations for Phase III clinical trials and successfully completed the first subject enrollment. This marks that the product development has made phased progress and further promoted the company’s vaccine development process. This Phase III clinical trial adopts a multi-center, randomized, double-blind, placebo-controlled design to evaluate the protective efficacy, safety and immunogenicity of the vaccine in Chinese infants and young children. https://finance.eastmoney.com/a/202504093371486634.html
- Source: drugdu
- 209
- April 11, 2025
Career Development Guide for API and Pharmaceutical Intermediate Sales Professionals

In the global pharmaceutical supply chain, sales professionals specializing in Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates play a crucial role. To excel in this competitive and dynamic international market, continuous enhancement of skills and knowledge is essential. Here are some key strategies to advance your career in pharmaceutical foreign trade sales: 1. Deepen Product and Industry Knowledge A thorough understanding of the chemical properties, production processes, quality standards, and applications of the APIs and intermediates you sell is fundamental to building trust with clients. Staying informed about global pharmaceutical regulations, market trends, and policy changes enables you to make informed decisions in the international marketplace. For instance, being familiar with the “Guidelines for the Development of the Pharmaceutical Industry” can provide insights into industry directions. 2. Enhance Cross-Cultural Communication and Negotiation Skills Engaging with clients from diverse cultural backgrounds is a daily aspect of international sales. Understanding and respecting ...
- Source: drugdu
- 242
- April 8, 2025
Zhongke Chuangxing Angel+Exclusive Investment Round in ‘Saiyun Biology’

Recently, Saiyun Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as “Saiyun Biotechnology”), a biotechnology company specializing in the development of international cutting-edge delivery carrier technology and innovative drug therapies, announced the completion of tens of millions of angel+round financing. This round of financing is exclusively invested by Zhongke Chuangxing, and the funds raised will mainly be used to accelerate the development process of the company’s self-developed pipelines. Saiyun Biotechnology is an enterprise dedicated to the research and development of targeted delivery technology and innovative drug therapies. It has successfully developed a biomimetic delivery system with independent intellectual property rights, which is different from mainstream delivery carrier systems. After rational transformation, the system can achieve precise cell delivery of various types of payloads, and has significant advantages in specificity recognition, payload compatibility, protection, and production cost. As an emerging type of delivery system, the research and development progress of “Saiyun Biology” ...
- Source: drugdu
- 208
- April 8, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.